Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI.

Jones NS, Yoshida K, Salphati L, Kenny JR, Durk MR, Chinn LW.

Clin Pharmacol Ther. 2019 Aug 2. doi: 10.1002/cpt.1599. [Epub ahead of print]

PMID:
31376152
2.

Absence of Pharmacokinetic Interactions Between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.

Jones NS, Winter H, Katsumoto TR, Florero M, Murray E, Walker H, Singh N, Chinn L.

J Pharmacol Exp Ther. 2019 Aug 1. pii: jpet.119.257089. doi: 10.1124/jpet.119.257089. [Epub ahead of print]

3.

Reaching to the Self: The Development of Infants' Ability to Localize Targets on the Body.

Leed JE, Chinn LK, Lockman JJ.

Psychol Sci. 2019 Jul;30(7):1063-1073. doi: 10.1177/0956797619850168. Epub 2019 Jun 7.

PMID:
31173538
4.

Reaching with one arm to the other: Coordinating touch, proprioception, and action during infancy.

Chinn LK, Hoffmann M, Leed JE, Lockman JJ.

J Exp Child Psychol. 2019 Jul;183:19-32. doi: 10.1016/j.jecp.2019.01.014. Epub 2019 Mar 6.

PMID:
30851626
5.

Development of Infant Reaching Strategies to Tactile Targets on the Face.

Chinn LK, Noonan CF, Hoffmann M, Lockman JJ.

Front Psychol. 2019 Jan 21;10:9. doi: 10.3389/fpsyg.2019.00009. eCollection 2019.

6.

In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.

Kou D, Zhang C, Yiu H, Ng T, Lubach JW, Janson M, Mao C, Durk M, Chinn L, Winter H, Wigman L, Yehl P.

Mol Pharm. 2018 Apr 2;15(4):1607-1617. doi: 10.1021/acs.molpharmaceut.7b01143. Epub 2018 Mar 19.

PMID:
29522347
7.

Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.

Herman AE, Chinn LW, Kotwal SG, Murray ER, Zhao R, Florero M, Lin A, Moein A, Wang R, Bremer M, Kokubu S, Serone AP, Hanze EL, Viberg A, Morimoto AM, Winter HR, Katsumoto TR.

Clin Pharmacol Ther. 2018 Jun;103(6):1020-1028. doi: 10.1002/cpt.1056. Epub 2018 Mar 23.

PMID:
29484638
8.

Cognitive control and midline theta adjust across multiple timescales.

Chinn LK, Pauker CS, Golob EJ.

Neuropsychologia. 2018 Mar;111:216-228. doi: 10.1016/j.neuropsychologia.2018.01.031. Epub 2018 Feb 2.

9.

Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria.

Kou D, Dwaraknath S, Fischer Y, Nguyen D, Kim M, Yiu H, Patel P, Ng T, Mao C, Durk M, Chinn L, Winter H, Wigman L, Yehl P.

Mol Pharm. 2017 Oct 2;14(10):3577-3587. doi: 10.1021/acs.molpharmaceut.7b00593. Epub 2017 Sep 8.

PMID:
28834434
10.

Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan S, Wong T, Melnick J, Theunissen JW, Flory MR, Houser D, Venstrom K, Levashova Z, Sauer P, Migone TS, van der Horst EH, Halcomb RL, Jackson DY.

Mol Pharm. 2015 Nov 2;12(11):3986-98. doi: 10.1021/acs.molpharmaceut.5b00432. Epub 2015 Oct 2.

PMID:
26393951
11.

CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.

Hayes GM, Cairns B, Levashova Z, Chinn L, Perez M, Theunissen JW, Liao-Chan S, Bermudez A, Flory MR, Schweighofer KJ, H van der Horst E.

Am J Transl Res. 2015 Jun 15;7(6):1181-8. eCollection 2015.

12.

A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.

Kim SY, Theunissen JW, Balibalos J, Liao-Chan S, Babcock MC, Wong T, Cairns B, Gonzalez D, van der Horst EH, Perez M, Levashova Z, Chinn L, D'Alessio JA, Flory M, Bermudez A, Jackson DY, Ha E, Monteon J, Bruhns MF, Chen G, Migone TS.

Blood Cancer J. 2015 May 29;5:e316. doi: 10.1038/bcj.2015.39.

13.

Altering Shank-Rear-Foot Joint Coupling During Gait With Ankle Taping in Patients With Chronic Ankle Instability and Healthy Controls.

Herb CC, Chinn L, Hertel J.

J Sport Rehabil. 2016 Feb;25(1):13-22. doi: 10-1123/jsr.2014-0244. Epub 2015 Feb 6.

PMID:
25658069
14.

Balance training and center-of-pressure location in participants with chronic ankle instability.

Mettler A, Chinn L, Saliba SA, McKeon PO, Hertel J.

J Athl Train. 2015 Apr;50(4):343-9. doi: 10.4085/1062-6050-49.3.94. Epub 2015 Jan 6.

15.

Antitumor activity of an anti-CD98 antibody.

Hayes GM, Chinn L, Cantor JM, Cairns B, Levashova Z, Tran H, Velilla T, Duey D, Lippincott J, Zachwieja J, Ginsberg MH, H van der Horst E.

Int J Cancer. 2015 Aug 1;137(3):710-20. doi: 10.1002/ijc.29415. Epub 2015 Jan 14.

16.

Creating developmentally auspicious school environments for African American boys.

Barbarin OA, Chinn L, Wright YF.

Adv Child Dev Behav. 2014;47:333-65. Review.

PMID:
25345001
17.

Gait kinematics after taping in participants with chronic ankle instability.

Chinn L, Dicharry J, Hart JM, Saliba S, Wilder R, Hertel J.

J Athl Train. 2014 May-Jun;49(3):322-30. doi: 10.4085/1062-6050-49.3.08. Epub 2014 May 19.

18.

Shank-rearfoot joint coupling with chronic ankle instability.

Herb CC, Chinn L, Dicharry J, McKeon PO, Hart JM, Hertel J.

J Appl Biomech. 2014 Jun;30(3):366-72. doi: 10.1123/jab.2013-0085. Epub 2013 Dec 17.

PMID:
24347533
19.

Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?

Micheli JE, Chinn LW, Shugarts SB, Patel A, Martin JN, Bangsberg DR, Kroetz DL.

Pharmacogenet Genomics. 2013 Nov;23(11):591-6. doi: 10.1097/FPC.0b013e32836533a5.

20.

Ankle kinematics of individuals with chronic ankle instability while walking and jogging on a treadmill in shoes.

Chinn L, Dicharry J, Hertel J.

Phys Ther Sport. 2013 Nov;14(4):232-9. doi: 10.1016/j.ptsp.2012.10.001. Epub 2013 Apr 25.

PMID:
23623243
21.

An overview of transporter information in package inserts of recently approved new molecular entities.

Agarwal S, Chinn L, Zhang L.

Pharm Res. 2013 Mar;30(3):899-910. doi: 10.1007/s11095-012-0924-0. Epub 2012 Nov 28. No abstract available.

PMID:
23187863
22.

Differential ability of selected postural-control measures in the prediction of chronic ankle instability status.

Knapp D, Lee SY, Chinn L, Saliba SA, Hertel J.

J Athl Train. 2011 May-Jun;46(3):257-62.

23.

Spatial postural control alterations with chronic ankle instability.

Pope M, Chinn L, Mullineaux D, McKeon PO, Drewes L, Hertel J.

Gait Posture. 2011 Jun;34(2):154-8. doi: 10.1016/j.gaitpost.2011.04.012. Epub 2011 May 20.

PMID:
21600773
24.

Genome-wide association study implicates PARD3B-based AIDS restriction.

Troyer JL, Nelson GW, Lautenberger JA, Chinn L, McIntosh C, Johnson RC, Sezgin E, Kessing B, Malasky M, Hendrickson SL, Li G, Pontius J, Tang M, An P, Winkler CA, Limou S, Le Clerc S, Delaneau O, Zagury JF, Schuitemaker H, van Manen D, Bream JH, Gomperts ED, Buchbinder S, Goedert JJ, Kirk GD, O'Brien SJ.

J Infect Dis. 2011 May 15;203(10):1491-502. doi: 10.1093/infdis/jir046.

25.

Genetic associations of variants in genes encoding HIV-dependency factors required for HIV-1 infection.

Chinn LW, Tang M, Kessing BD, Lautenberger JA, Troyer JL, Malasky MJ, McIntosh C, Kirk GD, Wolinsky SM, Buchbinder SP, Gomperts ED, Goedert JJ, O'Brien SJ.

J Infect Dis. 2010 Dec 15;202(12):1836-45. doi: 10.1086/657322.

26.

Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression.

Hendrickson SL, Lautenberger JA, Chinn LW, Malasky M, Sezgin E, Kingsley LA, Goedert JJ, Kirk GD, Gomperts ED, Buchbinder SP, Troyer JL, O'Brien SJ.

PLoS One. 2010 Sep 21;5(9):e12862. doi: 10.1371/journal.pone.0012862.

27.

Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains.

Kelly L, Fukushima H, Karchin R, Gow JM, Chinn LW, Pieper U, Segal MR, Kroetz DL, Sali A.

Protein Sci. 2010 Nov;19(11):2110-21. doi: 10.1002/pro.491.

28.

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB.

Pharmacogenet Genomics. 2011 Mar;21(3):152-61. doi: 10.1097/FPC.0b013e3283385a1c. No abstract available.

29.

Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code.

Liu A, Tran L, Becket E, Lee K, Chinn L, Park E, Tran K, Miller JH.

Antimicrob Agents Chemother. 2010 Apr;54(4):1393-403. doi: 10.1128/AAC.00906-09. Epub 2010 Jan 11.

30.

Rehabilitation of ankle and foot injuries in athletes.

Chinn L, Hertel J.

Clin Sports Med. 2010 Jan;29(1):157-67, table of contents. doi: 10.1016/j.csm.2009.09.006.

31.

South justice and healthcare.

Chinn L.

ANS Adv Nurs Sci. 2009 Apr-Jun;32(2):105. doi: 10.1097/01.ANS.0000352118.33447.95. No abstract available.

PMID:
19461226
32.

Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.

van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey TC, Sato AK.

Neoplasia. 2009 Apr;11(4):355-64.

33.

Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila.

Mayer F, Mayer N, Chinn L, Pinsonneault RL, Kroetz D, Bainton RJ.

J Neurosci. 2009 Mar 18;29(11):3538-50. doi: 10.1523/JNEUROSCI.5564-08.2009.

34.

Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.

Byakika-Tusiime J, Chinn LW, Oyugi JH, Obua C, Bangsberg DR, Kroetz DL.

PLoS One. 2008;3(12):e3981. doi: 10.1371/journal.pone.0003981. Epub 2008 Dec 19.

35.

The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo.

van der Horst EH, Frank BT, Chinn L, Coxon A, Li S, Polesso F, Slavin A, Ruefli-Brasse A, Wesche H.

Neoplasia. 2008 Apr;10(4):340-7.

36.

The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.

Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, Giacomini KM, Kroetz DL.

J Pharmacol Exp Ther. 2008 Jun;325(3):859-68. doi: 10.1124/jpet.108.136523. Epub 2008 Mar 25.

37.

Substrate-dependent effects of human ABCB1 coding polymorphisms.

Gow JM, Hodges LM, Chinn LW, Kroetz DL.

J Pharmacol Exp Ther. 2008 May;325(2):435-42. doi: 10.1124/jpet.107.135194. Epub 2008 Feb 20.

38.

The effects of ABCB1 3'-untranslated region variants on mRNA stability.

Gow JM, Chinn LW, Kroetz DL.

Drug Metab Dispos. 2008 Jan;36(1):10-5. Epub 2007 Oct 16.

PMID:
17940136
39.

Exophytic growths on the gingiva. Squamous papillomas.

Chinn L.

Gen Dent. 2007 Jul-Aug;55(4):367, 371. No abstract available.

PMID:
17682648
40.

Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein.

Chinn LW, Gow JM, Tse MM, Becker SL, Kroetz DL.

J Antimicrob Chemother. 2007 Jul;60(1):61-7. Epub 2007 May 17.

PMID:
17510066
41.

ABCB1 pharmacogenetics: progress, pitfalls, and promise.

Chinn LW, Kroetz DL.

Clin Pharmacol Ther. 2007 Feb;81(2):265-9. Review.

PMID:
17259950
42.

PharmGKB submission update: IV. PMT submissions of genetic variations in ATP-Binding cassette transporters to the PharmGKB network.

Nguyen TD, Gow JM, Chinn LW, Kelly L, Jeong H, Huang CC, Stryke D, Kawamoto M, Johns SJ, Carlson E, Taylor T, Ferrin TE, Sali A, Giacomini KM, Kroetz DL.

Pharmacol Rev. 2006 Mar;58(1):1-2. No abstract available.

PMID:
16507877
43.

Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1.

van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J, Rong M, Li S, See LH, Nguyen KQ, Hoey T, Wesche H, Powers S.

Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15901-6. Epub 2005 Oct 24.

44.

A nonpeptide provides insight into mechanisms that regulate Drosophila melanogaster heart contractions.

Mispelon M, Thakur K, Chinn L, Owen R, Nichols R.

Peptides. 2003 Oct;24(10):1599-605.

PMID:
14706539
45.

A gut reaction.

Chinn L.

Nurs Prax N Z. 1993 Jul;8(2):47. No abstract available.

PMID:
8364345
46.
47.

Effect of 23-methyl-21-norcholest-5-ene-3 beta, 23,25-triol on hepatic cholesterol 7 alpha-hydroxylase activity in the rat.

Nicholson N, Flanders L, Desai BN, Chinn L.

J Steroid Biochem. 1979 Jun;10(6):709-10. No abstract available.

PMID:
470391
48.

Hypolipidemic activity of 5-aryl-3-methylvaleric acid derivatives.

Dygos JH, Jett CM, Chinn LJ, Miller JE.

J Med Chem. 1977 Dec;20(12):1705-8.

PMID:
592342
49.

Spironolactone: diversity in metabolic pathways.

Karim A, Hribar J, Doherty M, Aksamit W, Chappelow D, Brown E, Markos C, Chinn LJ, Liang D, Zagarella J.

Xenobiotica. 1977 Oct;7(10):585-600. No abstract available.

PMID:
410173
50.

Ring D oxygenated Spirolactones. Characterization of human metabolic product of spironolactone.

Chinn LJ, Brown EA, Mizuba SS, Karim A.

J Med Chem. 1977 Mar;20(3):352-5.

PMID:
845867

Supplemental Content

Support Center